Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer.
|
16954431 |
2006 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We transfected human anaplastic (FRO) and medullary (TT) thyroid cancer-derived cell lines that were unable to take up iodine with human NIS cDNA.
|
16537683 |
2006 |
Thyroid carcinoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Therefore, tRA treatment and NIS gene transfection are potential tools for the diagnosis and treatment of thyroid cancer.
|
17045167 |
2006 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Therefore, tRA treatment and NIS gene transfection are potential tools for the diagnosis and treatment of thyroid cancer.
|
17045167 |
2006 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer.
|
16954431 |
2006 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of the sodium iodide symporter (NIS) in the thyroid gland provides for effective imaging and treatment of thyroid cancer using radiolabeled iodide.
|
15746050 |
2005 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sodium/iodide symporter (NIS) is a membrane glycoprotein that mediates active 131I uptake during the treatment of cancer of the thyroid gland and extrathyroidal tissues.
|
16264365 |
2005 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NIS is a target for radioiodide imaging and therapeutic ablation of thyroid carcinomas and has the potential for similar use in breast cancer treatment.
|
15472226 |
2004 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Qualitative analysis of baseline and stimulated TG, NIS and PDS mRNA showed high sensitivity but low specificity in the prediction of thyroid cancer recurrence or metastases (accuracy under THST = 51%, 43% and 54%, respectively), whereas TPO and TSHR mRNA assays had higher specificity but low sensitivity, with accuracy under THST of 67% and 61%, respectively, that improved when these tests were combined.
|
15170676 |
2004 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The transcriptional regulation of the human sodium/iodide symporter (NIS) gene in normal and transformed thyroid cells is a crucial issue in attempting to restore iodide uptake and use radioiodine as a therapeutic treatment of thyroid cancer.
|
14630715 |
2004 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cloning of the NIS gene and the development of specific NIS antibodies have allowed the characterization of the pathogenic role of NIS in thyroid cancer, thyroid autoimmune diseases, congenital hypothyroidism and other, non-thyroidal human diseases.
|
14870777 |
2004 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sodium iodide symporter (NIS) mediates iodide uptake in thyroid cells and enables the effective radioiodide treatment of thyroid cancers.
|
12699587 |
2003 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS.
|
15062578 |
2003 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results have indicated for the first time that reduced levels of CREB expression are a feature of thyroid carcinomas, and confirm that different factors are likely to modulate NIS expression.
|
12720543 |
2003 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioiodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy.
|
12477251 |
2002 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The increased NIS expression and reduced PDS expression may make radioiodine therapy more effective in patients with thyroid cancer, especially when the tumors have no or low uptake of radioiodine.
|
12490845 |
2002 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sodium/iodide symporter (NIS) is a key protein in iodide transport by thyroid cells and this activity is a prerequisite for effective radioiodide treatment of thyroid cancer.
|
12475396 |
2002 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioactive iodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by the sodium iodide symporter (NIS), is the first rate-limiting step in iodide accumulation which provides a mechanism for effective radioiodide treatment for patients with thyroid cancer.
|
12170377 |
2002 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Deficient CRE-like sequence binding protein(s) that bind to the hNUE in normal thyroid cells may be responsible for reduced NIS gene expression in some thyroid carcinomas.
|
12351692 |
2002 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A mammalian NIS expression vector was constructed and used to generate six stable NIS-expressing cancer cell lines (three derived from thyroid carcinoma, two from colon carcinoma, one from glioblastoma).
|
12111124 |
2002 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several investigators have shown that gene transfer of NIS into a variety of cell types confers increased radioiodine uptake by up to several hundredfold that of controls in nonthyroid cancers as well as in thyroid cancer.
|
12215558 |
2002 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both up- and down-regulation of NIS gene expression have been reported in thyroid cancer using several different methods.
|
11301345 |
2001 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer.
|
11573141 |
2001 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas.
|
11272095 |
2001 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, 2 neoplastic thyroid tissues carrying undetectable PDS mRNA maintained NIS transcript, and 3 thyroid carcinomas negative for NIS mRNA retained the expression of PDS gene.
|
11454507 |
2001 |